MEDP Stock Analysis: Medpace Holdings | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 17.226m USD | 12M Return: 21.4% | US58506Q1094 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 135M
EPS Trend: 99.3%
Qual. Beats: 4
Rev. Trend: 98.4%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Medpace Holdings, Inc. (NASDAQ: MEDP) is a clinical research organization (CRO) that provides drug and medical device development services to the pharmaceutical, biotechnology, and medical device industries. Founded in 1992 and headquartered in Cincinnati, Ohio, the company operates across North America, Europe, Asia, South America, Africa, and Australia, supporting clinical trials from Phase I through Phase IV across a wide range of therapeutic areas.
The companys service portfolio spans the full clinical development lifecycle, including development plan design, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance, and new drug application submissions, along with post-marketing clinical support. Medpace further provides specialized offerings such as bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials.
As a large-cap stock in the GICS Life Sciences Tools & Services sub-industry, Medpace is part of the broader outsourced drug development sector, where CROs help sponsors reduce trial timelines and costs. Listed on NASDAQ since its August 2016 IPO, the company operates on a global scale with an asset-light, services-driven business model that relies on long-term contracts with biopharma and medical device sponsors.
- Biotech funding recovery boosts clinical trial bookings growth
- Small-mid biotech exposure drives backlog cancellation risk
- Labor cost inflation pressures operating margins
| Net Income: 491.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.36 > 0.02 and ΔFCF/TA -1.24 > 1.0 |
| NWC/Revenue: -13.84% < 20% (prev -31.35%; Δ 17.51% < -1%) |
| CFO/TA 0.37 > 3% & CFO 752.7m > Net Income 491.5m |
| Net Debt (-382.6m) to EBITDA (602.2m): -0.64 < 3 |
| Current Ratio: 0.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (28.8m) vs 12m ago -4.65% < -2% |
| Gross Margin: 28.76% > 18% (prev 31.62%; Δ -2.86% > 0.5%) |
| Asset Turnover: 153.3% > 50% (prev 142.0%; Δ 11.34% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: -0.19 (Total Current Assets 1.05b - Total Current Liabilities 1.44b) / Total Assets 2.06b |
| B: -0.25 (Retained Earnings -511.4m / Total Assets 2.06b) |
| C: 0.32 (EBIT TTM 588.0m / Avg Total Assets 1.81b) |
| D: 0.27 (Book Value of Equity 433.9m / Total Liabilities 1.62b) |
| Altman-Z'' = 0.42 = B |
| DSRI: 0.94 (Receivables 441.8m/377.9m, Revenue 2.78b/2.23b) |
| GMI: 1.10 (GM 31.62% / 28.76%) |
| AQI: 0.70 (AQ_t 0.35 / AQ_t-1 0.50) |
| SGI: 1.25 (Revenue 2.78b / 2.23b) |
| TATA: -0.13 (NI 491.5m - CFO 752.7m) / TA 2.06b) |
| Beneish M = -3.00 (Cap -4..+1) = A |
As of October 01, 2026, the stock is trading at USD 624.18 with a total of 305,790 shares traded. Over the past week, the price has changed by +1.14%, over one month by +5.08%, over three months by +17.86% and over the past year by +21.40%.
Current recommended Stop Loss: 606.20 (which is 2.9% or 1.2 ATR below the current price).
Medpace Holdings has received a consensus analysts rating of 3.33. Therefore, it is recommended to hold MEDP.
- StrongBuy: 2
- Buy: 0
- Hold: 10
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 581.8 | -6.8% |
P/E Trailing = 36.239
P/E Forward = 32.5733
P/S = 6.1912
P/B = 40.5801
P/EG = 2.9997
Revenue TTM = 2.78b USD
EBIT TTM = 588.0m USD
EBITDA TTM = 602.2m USD
Long Term Debt = unknown (none)
Short Term Debt = 23.2m USD (from shortTermDebt, last fiscal year)
Debt = 120.1m USD (from shortLongTermDebtTotal, last quarter) (leases 120.1m already included)
Net Debt = -382.6m USD (calculated: Debt 120.1m - CCE 502.7m)
Enterprise Value = 16.8b USD (17.2b + Debt 120.1m - CCE 502.7m)
Interest Coverage Ratio = unknown (Ebit TTM 588.0m / Interest Expense TTM 0.0)
EV/FCF = 22.96x (Enterprise Value 16.8b / FCF TTM 733.5m)
FCF Yield = 4.35% (FCF TTM 733.5m / Enterprise Value 16.8b)
FCF Margin = 26.36% (FCF TTM 733.5m / Revenue TTM 2.78b)
Net Margin = 17.67% (Net Income TTM 491.5m / Revenue TTM 2.78b)
Gross Margin = 28.76% ((Revenue TTM 2.78b - Cost of Revenue TTM 1.98b) / Revenue TTM)
Gross Margin QoQ = 28.51% (prev 27.78%)
Tobins Q-Ratio = 8.19 (Enterprise Value 16.8b / Total Assets 2.06b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 120.1m)
Taxrate = 17.94% (107.4m / 598.9m)
NOPAT = 482.5m (EBIT 588.0m * (1 - 17.94%))
Current Ratio = 0.73 (Total Current Assets 1.05b / Total Current Liabilities 1.44b)
Debt / Equity = 0.28 (Debt 120.1m / totalStockholderEquity, last quarter 433.9m)
Debt / EBITDA = -0.64 (Net Debt -382.6m / EBITDA 602.2m)
Debt / FCF = -0.52 (Net Debt -382.6m / FCF TTM 733.5m)
Total Stockholder Equity = 446.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 27.09% (Net Income 491.5m / Total Assets 2.06b)
RoE = 110.1% (Net Income TTM 491.5m / Total Stockholder Equity 446.2m)
RoCE = 94.57% (EBIT 588.0m / Capital Employed (Total Assets 2.06b - Current Liab 1.44b))
RoIC = 95.39% (NOPAT 482.5m / Invested Capital 505.8m)
WACC = 8.23% (E(17.2b)/V(17.3b) * Re(8.29%) + D(120.1m)/V(17.3b) * Rd(0.0%) * (1-Tc(0.18)))
Discount Rate = 8.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.56 | Cagr: -4.63%
[DCF] Terminal Value 77.97% ; FCFF base≈672.0m ; Y1≈770.4m ; Y5≈1.13b
[DCF] Fair Price = 625.0 (EV 17.1b - Net Debt -382.6m = Equity 17.4b / Shares 27.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.28 | EPS CAGR: 28.26% | SUE: 0.84 | # QB: 4
Revenue Correlation: 98.40 | Revenue CAGR: 16.36% | SUE: 0.80 | # QB: 0
EPS current Quarter (2026-09-30): EPS=4.44 | Chg30d=+0.00% | Revisions=+50% | Analysts=8
EPS current Year (2026-12-31): EPS=17.70 | Chg30d=+0.00% | Revisions=+75% | GrowthEPS=+15.9% | GrowthRev=+12.7%
EPS next Year (2027-12-31): EPS=19.31 | Chg30d=+0.00% | Revisions=+62% | GrowthEPS=+9.1% | GrowthRev=+6.1%
[Analyst] Revisions Ratio: +76% (up=24, down=2)